← Back to Search

Advance Care Planning Approaches for Older Adults (EQUALACP Trial)

N/A
Waitlist Available
Led By Kimberly Johnson, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
age 65 or greater
Serious or chronic illness including: metastatic cancer; end stage renal disease; advanced liver disease, heart disease or lung disease; amyotrophic lateral sclerosis, severe Parkinson's disease; 2 or more unplanned hospitalizations in the last year; requiring assistance with any basic activity of daily living
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months, 6 months, one year
Awards & highlights

EQUALACP Trial Summary

This trial will compare two approaches to advance care planning (ACP) - a structured conversation led by a trained professional, and a patient-driven form written in plain language - to see which is more effective among older African Americans and older Whites.

Who is the study for?
This trial is for older adults aged 65 or above, living in their own homes, who can make decisions about their future healthcare. They must have a serious illness like advanced cancer, heart or lung disease, kidney failure, ALS or severe Parkinson's disease. Participants should not be surprised if told they might pass away within the next year and may need help with daily activities.Check my eligibility
What is being tested?
The study compares two ways of planning future healthcare: one uses a structured conversation guided by trained facilitators (Respecting Choices First Steps), while the other involves patients filling out an easy-to-understand form called Five Wishes on their own.See study design
What are the potential side effects?
Since this trial focuses on advance care planning rather than medical treatments, there are no direct physical side effects. However, discussing end-of-life care can be emotionally challenging and may cause distress.

EQUALACP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 65 years old or older.
Select...
I have a serious illness or have been frequently hospitalized.
Select...
I have a serious illness or have been hospitalized twice last year.
Select...
I am 65 years old or older.

EQUALACP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months, 6 months, one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months, 6 months, one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of African Americans who complete advance care planning
Proportion of Whites who complete advance care planning
Secondary outcome measures
Difference in Proportion of Whites versus African Americans who complete advance care planning
Patient Quality of Life
Patient Readiness to Engage in Advance Care Planning

EQUALACP Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Structured Advance Care PlanningExperimental Treatment1 Intervention
In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
Group II: Patient Driven Advance Care PlanningActive Control1 Intervention
In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,358 Previous Clinical Trials
3,419,279 Total Patients Enrolled
Kimberly Johnson, MDPrincipal InvestigatorDuke University

Media Library

Five Wishes Form Clinical Trial Eligibility Overview. Trial Name: NCT03516994 — N/A
Interstitial Lung Disease Research Study Groups: Structured Advance Care Planning, Patient Driven Advance Care Planning
Interstitial Lung Disease Clinical Trial 2023: Five Wishes Form Highlights & Side Effects. Trial Name: NCT03516994 — N/A
Five Wishes Form 2023 Treatment Timeline for Medical Study. Trial Name: NCT03516994 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In what regional scope are the trials being conducted?

"This experimental medication is being tested in 7 clinical trial sites, including University of Texas Southwestern in Dallas, Emory University in Atlanta, and the University of Alabama at Birmingham."

Answered by AI

Is enrollment currently available for this medical trial?

"Information on clinicaltrials.gov confirms that this medical trial is no longer recruiting patients, having been initially posted back in August 2018 and last updated December 2021. However, there are 2,402 other trials actively looking for participants presently."

Answered by AI

Who else is applying?

What state do they live in?
Oregon
How old are they?
65+
What site did they apply to?
University of Texas Southwestern
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
2018. "Reducing Disparities in the Quality of Advance Care Planning for Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03516994.
All > Lou Gehrigs Disease > Congestive Heart Failure
~118 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top